Associated tags: PTM-101, Biotechnology, Peter MacCallum Cancer Centre, Toxicity, FACS, Panther, University, Paclitaxel, Associate, Massachusetts Institute of Technology School of Engineering, Pancreas, MD, Safety, Peter, Doctor of Philosophy, Medical imaging, Pharmaceutical industry, PanTher Therapeutics, Senior, Physician
Oncology,
Health,
Surgery,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Toxicity,
Infection,
Associate,
Patient,
Cancer,
Doctor of Philosophy,
MD,
Panther,
AACR,
Pancreatic cancer,
Neoplasm,
Clinical trial,
Therapy,
Paclitaxel,
Pancreas,
Pancreatitis,
Safety,
Monash University,
Prognosis,
Pharmaceutical industry PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
Key Points:
- PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
- Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
- Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
- Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.
Oncology,
Medical Devices,
Health,
Surgery,
Clinical Trials,
Biotechnology,
Boston University,
Toxicity,
Hematology,
Genetics,
Executive,
Monoclonal antibody,
Shire (pharmaceutical company),
Merck,
Acquisition,
BMS,
Cancer,
University,
Doctor of Philosophy,
Panther,
MBA,
Marketing,
Neoplasm,
Therapy,
Chemical engineering,
Genetics Institute,
F-star,
FDA,
Pharmaceutical industry PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
Key Points:
- PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
- “John has been an outstanding addition to our Board and management team since joining the company in September.
- His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
- During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.
Retrieved on:
Wednesday, October 6, 2021
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
MBBS,
Therapy,
Clinical trial,
Medical college,
Pharmacokinetics,
Medical College of Wisconsin,
The Alfred Hospital,
MIT,
Pancreatic cancer,
Royal Australasian College of Surgeons,
Royal Australasian College,
Pancreatic tumor,
Cancer,
Patient,
Monash University,
Physician,
MD,
Senior,
Toxicity,
FACS,
Panther,
University,
Paclitaxel,
Associate,
Technology,
Peter MacCallum Cancer Centre,
Pancreas,
Massachusetts Institute of Technology School of Engineering,
Safety,
Peter,
Doctor of Philosophy,
Medical imaging,
Pharmaceutical industry,
PTM-101,
PanTher Therapeutics,
PTM-101,
PANTHER THERAPEUTICS PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, announced today the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer.
Key Points:
- PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, announced today the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer.
- Pancreatic cancer has one of the poorest prognoses of all malignancies, and responses to currently available systemic therapies are inadequate.
- This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma.
- PanTher Therapeutics (PanTher) is a clinical-stage oncology company revolutionizing cancer care with a proprietary treatment platform designed to enhance therapeutic response while minimizing side effects.
